Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ALN-GO1 in primary hyperoxaluria type 1
NL-OMON50391Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Aug 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Incidence of adverse events. Started Aug 2018; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NL-OMON50391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50391.